First-in-human safety study of pancreatic islet transplantation without immune suppression in adult subjects with type 1 diabetes

2023-507988-19-00 Protocol UP421-ET1D Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 8 Mar 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol UP421-ET1D

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 2
Countries 1
Sites 1

Diabetes type I

Key facts

Sponsor
Uppsala University Hospital
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
8 Mar 2024 → ongoing
Decision date (initial)
2023-11-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Diabetes type I

VersionLevelCodeTermSystem organ class
21.1 LLT 10045228 Type I diabetes mellitus 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Uppsala University Hospital

Sponsor organisation
Uppsala University Hospital
Address
Akademiska Sjukhuset
City
Uppsala
Postcode
751 85
Country
Sweden

Scientific contact point

Organisation
Uppsala University Hospital
Contact name
Per-Ola Carlsson

Public contact point

Organisation
Uppsala University Hospital
Contact name
Per-Ola Carlsson

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ongoing, recruitment ended 2 1
Rest of world 0

Investigational sites

Sweden

1 site · Ongoing, recruitment ended
Uppsala University Hospital
Endocrinology and Diabetology, Akademiska Sjukhuset, 751 85, Uppsala

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2024-03-08 2024-12-01 2025-10-01

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-04 Sweden Acceptable
2023-11-13
2023-11-16
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-03 Sweden Acceptable
2024-05-20
2024-05-20
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-10 Sweden Acceptable
2026-01-30
2026-01-30